Biotech

Companies & Industries News

Biotech Companies & Industries Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Biotech

Top news of the week: 21.09.2022.

#atopicdermatitis
#PharmaScrip
#COVIDPandemic
#LifeScience
#BioSpace
#PresidentJoeBiden
#COVID
#DigitalTransformation
#NBTintheNews
#ClinicalAttrition

@sanofi shared
On Sep 15, 2022
#Atopicdermatitis is a chronic type 2 inflammatory skin disease with 85-90% of patients developing symptoms before 5 years of age. Find out more about today’s news: https://t.co/vyR7F8n3wB @Regeneron @TheLancet https://t.co/c4omkkI6tU
Open
Media Update: Positive Dupixent® (dupilumab) Phase 3 data in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis published...

Media Update: Positive Dupixent® (dupilumab) Phase 3 data in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis published...

Disease measures included additional EASI outcomes, itch reduction, percent of body surface area affected, skin pain, disease severity as measured by the Patient Oriented Eczema …

@biospace shared
On Sep 20, 2022
President Joe Biden declared the COVID-19 pandemic over but recognized there is still an ongoing problem with viral infections. #PresidentJoeBiden #COVID #COVIDPandemic #LifeScience #BioSpace https://t.co/vDa9wYXbCK
Open
Biden Declares 'COVID-19 Pandemic Over' as Biopharma Reacts (Updated)

Biden Declares 'COVID-19 Pandemic Over' as Biopharma Reacts (Updated)

Pres. Joe Biden declared the COVID-19 pandemic over. Biopharma stocks react as vaccines and antivirals are still in development.

@pharmaphorum shared
On Sep 21, 2022
. @pumabiotech resurrects @TakedaPharma's aurora kinase A inhibitor alisertib, which failed a phase 3 trial in #lymphoma, licensing rights to the drug in a deal worth up to $294m $TAK $PBYI https://t.co/rEd6HMVoqu
Open
Takeda farms out cancer drug alisertib to Puma Biotech

Takeda farms out cancer drug alisertib to Puma Biotech

Puma Biotech resurrects Takeda's aurora kinase A inhibitor alisertib, which failed a phase 3 trial in lymphoma, licensing rights to the drug in a deal worth up to $294m

@PharmaScrip shared
On Sep 21, 2022
Pfizer Builds On AI/ML Pact With CytoReason With New Five-Year Deal https://t.co/whtZrii7fM #PharmaScrip
Open
Pfizer Builds On AI/ML Pact With CytoReason With New Five-Year Deal

Pfizer Builds On AI/ML Pact With CytoReason With New Five-Year Deal

<p><span>Deal Snapshot: The companies first partnered in January 2019, with a focus on more than 20 diseases. The renewed deal will support development of additional disease models using ...

@PharmaScrip shared
On Sep 15, 2022
Transformation Time For Minoryx With Leriglitazone Filing https://t.co/r2FVRGp2hA #PharmaScrip
Open
Transformation Time For Minoryx With Leriglitazone Filing

Transformation Time For Minoryx With Leriglitazone Filing

<p>The Spanish biotech, formed in 2011, is preparing for the potential European launch of leriglitazone for X-linked adrenoleukodystrophy after the EMA accepted its file.</p> <br ...

@Regeneron shared
On Sep 15, 2022
.@TheLancet has published Phase 3 data for our medicine in children aged 6 months to 5 years with uncontrolled moderate-to-severe #atopicdermatitis. Learn more: https://t.co/OLyBc0V1Qb @Sanofi
Open
Positive Dupixent® (dupilumab) Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Published in The Lancet

Positive Dupixent® (dupilumab) Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Published in The Lancet

Dupixent is the first and only biologic that significantly improved skin clearance, and reduced itch and overall disease severity in children as young as 6 months old in a Phase 3 trial ...

@NatureBiotech shared
On Sep 19, 2022
One month after the FDA gave its green light to @bluebirdbio's Zynteglo to treat β-thalassemia, the agency approves the company's Skysona, a gene therapy for early, active cerebral adrenoleukodystrophy #NBTintheNews https://t.co/me5p5bboXk
Open
Bluebird lands another rare disease gene therapy OK — but there are a few caveats to note

Bluebird lands another rare disease gene therapy OK — but there are a few caveats to note

Relative to the protracted journey of developing a gene therapy delivered by a lentiviral vector, the speed at which bluebird bio moved from having one approved product to two was extremely ...

@ideapharma shared
On Sep 20, 2022
RT @Xtalks: Join @CausalyAI's webinar with an expert panel of speakers including @ideapharma to learn how AI can augment & empower humans to make better quality decisions in R&D, leading to improved clinical attrition. https://t.co/4ucNhcJKKz #DigitalTransformation #AI #ClinicalAttrition https://t.co/YwfXPPNWzo
Open
Improving Clinical Attrition and Decision-Making with Artificial Intelligence

Improving Clinical Attrition and Decision-Making with Artificial Intelligence

Register to learn how AI can augment and empower humans to make better quality decisions in R&D, leading to improved clinical attrition.

Read more:
weekly 21.09.2022
View archives
Back to home

Subscribe to Biotech - Companies & Industries.

Avoid an information overload and get the most trusted industry news hand-picked by the top Experts. Sign up for the weekly Biotech - Companies & Industries.
Privacy Policy

Sign up for the weekly Biotech - Companies & Industries newsletter

Never again miss anything or anyone that matter in Biotech

Sign up and receive the Biotech - Companies & Industries weekly email newsletter directly to your inbox. Make more informed business decisions based on insight for the most trusted industry experts, faster.
Privacy Policy